Sanofi Publishes Rules for Clinical Trial Social Media Engagement
Pharmaceutical company Sanofi has released guidelines detailing its social media use for clinical trial communications. The rules outline compliance frameworks and user guidance for educational content.
Sanofi, a global pharmaceutical company, has published official rules of engagement for its social media presence concerning clinical trials. These guidelines define how the company communicates on social platforms, aiming to provide targeted and regulatory-compliant information about clinical trials and medical conditions.
The company states that its social media pages are intended for targeted, paid content designed to educate specific audiences about clinical trials and health issues. These platforms are not designed for reporting side effects, providing medical advice, or conducting personal medical consultations. Sanofi emphasizes that all content is reviewed by qualified personnel and an ethics committee before publication.
The rules also establish strict moderation practices. Sanofi reserves the right to block users who violate the guidelines and to remove content that breaches regulatory requirements or platform policies. The company may also discontinue these pages and their content at any time. Users are required to adhere to the terms of service of each social media platform used.
Sanofi stresses that the information presented on these pages is for educational purposes only and should not substitute professional medical advice. While the company verifies the accuracy of its posted content and ensures regulatory compliance, it does not vouch for the accuracy of user-generated information. Users are instructed to report any unexpected medical events or side effects immediately through a dedicated online portal, a local Sanofi affiliate, or their healthcare provider.